| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10973811 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10894012 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10857095 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10420760 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10413505 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10149843 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10016407 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US9867815 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10933060 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US11040032 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10231961 | OMNIVIUM PHARMS | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
Numbrino is owned by Omnivium Pharms.
Numbrino contains Cocaine Hydrochloride.
Numbrino has a total of 11 drug patents out of which 0 drug patents have expired.
Numbrino was authorised for market use on 10 January, 2020.
Numbrino is available in solution;nasal dosage forms.
Numbrino can be used as method for the induction of local anesthesia of the mucous membranes, a method for treating a subject with uveal melanoma with unresectable hepatic metastases, method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment, method of administering a local anesthetic to the mucous membranes, method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes, method of administering a local anesthetic to the mucous membranes in patients with renal impairment.
Drug patent challenges can be filed against Numbrino from 14 December, 2021.
The generics of Numbrino are possible to be released after 07 February, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
| New Product(NP) | Jan 10, 2023 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 10 January, 2020
Treatment: A method for treating a subject with uveal melanoma with unresectable hepatic metastases; Method for the induction of local anesthesia of the mucous membranes; Method for the induction of local anesth...
Dosage: SOLUTION;NASAL
NUMBRINO family patents
